HALOTESTIN (Fluoxymesterone) by Meditech is a pharmaceutical-grade oral anabolic-androgenic steroid formulated at 10 mg per tablet, supplied in sachets or blister packs of 50 tablets. Fluoxymesterone is a 17α-alkylated halogenated testosterone derivative with an extensive clinical and pharmacological research history, documented as one of the most potent androgenic compounds in comparative anabolic-androgenic steroid literature — characterized by an exceptionally high androgenic-to-anabolic ratio that distinguishes it pharmacologically from the majority of anabolic-androgenic compounds and produces a distinct performance parameter profile in research subject populations.
 
✔ Key Research Insights
Studied for its exceptionally potent androgenic activity, with a documented androgenic-to-anabolic ratio significantly elevated relative to testosterone and most other anabolic-androgenic compounds in comparative steroid pharmacology research, producing pronounced effects on strength parameters and central nervous system stimulation in research subjects
Investigated for its effects on raw strength indices and power output parameters in documented subject populations, with strength gains documented as disproportionately pronounced relative to lean mass accrual — a pharmacological characteristic of particular research interest distinguishing fluoxymesterone from primarily mass-accruing anabolic compounds in comparative literature
Researched for its influence on central nervous system stimulation and aggression-related parameters, with documented effects on training intensity and neuromuscular activation referenced across comparative androgenic steroid pharmacology research
Examined for its effects on muscular hardness and vascular parameters in research subjects, associated with fluoxymesterone's non-aromatizing profile and absence of estrogenic fluid retention in documented clinical observations
Documented for its erythropoietic activity, with established clinical applications in anemia management — including aplastic anemia and anemia associated with androgen deficiency — representing well-characterized therapeutic documentation in hematology and endocrinology literature
Researched for its pronounced hepatotoxic profile, documented in clinical literature as among the most significant of any oral anabolic-androgenic compound due to its combined 17α-alkylation and halogenated structure — with hepatic function monitoring referenced consistently and emphatically across all fluoxymesterone clinical literature
Documented for its complete absence of aromatization to estrogen and strong suppressive effects on the hypothalamic-pituitary-testicular axis in comparative endocrinological research
Manufactured by Meditech to pharmaceutical-grade reliability and consistent potency standards
 
📦 Product Specifications
Manufacturer: Meditech
Product: HALOTESTIN
Molecule: Fluoxymesterone
Concentration: 10 mg per tablet
Appearance: Pink octagon-shaped tablet imprinted with logo "M"
Packing: 50 tablets per sachet or 50 tablets per blister pack
Dosage considerations may vary. Consulting a qualified professional is recommended.
 
⚙ How It Works
Fluoxymesterone is a 17α-alkylated, 9α-fluoro, 11β-hydroxy testosterone derivative administered orally. Its halogenated structure — incorporating fluorine at the 9α position and a hydroxyl group at the 11β position — confers dramatically elevated androgenic receptor binding potency relative to testosterone, producing the exceptionally high androgenic-to-anabolic ratio documented in comparative steroid pharmacology research. The 17α-alkylation modification enables consistent oral bioavailability by conferring hepatic first-pass metabolism resistance, while concurrently contributing to the pronounced hepatotoxic potential documented across all fluoxymesterone clinical literature — a consideration of particular clinical emphasis given that the compound's halogenated structure further compounds hepatic stress relative to standard 17α-alkylated oral anabolic steroids. Fluoxymesterone exerts its primary pharmacological effects through exceptionally high-affinity androgen receptor binding in muscle tissue and central nervous system target sites, with documented downstream influences on protein synthesis, nitrogen retention, and neuromuscular activation in research literature. Its halogenated structure confers complete resistance to aromatization via the aromatase enzyme, resulting in the documented absence of estrogenic effects including fluid retention across research subject populations. The pronounced central nervous system androgenic stimulation documented in fluoxymesterone research — manifesting as elevated aggression, competitive drive, and training intensity in subject populations — represents a pharmacologically distinct research area relative to other anabolic-androgenic compounds, attributed to high-affinity androgen receptor interaction in neurological target tissues. Graduated pyramid dosing protocols and strictly limited cycle durations are referenced consistently across fluoxymesterone clinical literature as essential administration considerations given its documented hepatotoxic profile and pronounced hypothalamic-pituitary-testicular axis suppression. Established therapeutic applications documented in medical literature include hypogonadism management, anemia treatment, and historically, breast cancer palliation — representing a well-characterized clinical documentation base across endocrinology and hematology research.
 
⭐ Product Overview
Manufactured by Meditech to pharmaceutical-grade reliability and consistent potency standards
One of the most potent androgenic compounds documented in comparative anabolic-androgenic steroid pharmacology literature, with a distinct strength and neuromuscular activation research profile relative to primarily mass-accruing anabolic compounds
Pronounced hepatotoxic profile referenced emphatically across all fluoxymesterone clinical literature, necessitating strict cycle duration limitations and hepatic function monitoring in all documented research protocols
Distinctively identified pink octagon tablet presentation at 10 mg per tablet for consistent product recognition
Available in both sachet and blister pack formats providing 50 tablets per unit
Widely referenced in anabolic pharmacology, hematology, and endocrinological research literature under the fluoxymesterone and Halotestin designations